NasdaqGM:NTLABiotechs
Intellia Therapeutics (NTLA) Resumes Key Trials, Is The Undervalued Case Still Convincing?
The FDA’s decision to lift clinical holds on Intellia Therapeutics (NTLA)’s MAGNITUDE and MAGNITUDE-2 trials has refocused attention on the stock, as patient enrollment for its in vivo CRISPR programs can now continue.
See our latest analysis for Intellia Therapeutics.
Despite the regulatory relief, Intellia Therapeutics’ 1-day share price return declined 1.95% to US$13.04, extending a 7-day share price decline of 22.57%. However, the year to date share price return of 41.59% contrasts with a...